133208-93-2

Usage

Uses

Used in Pharmaceutical Industry:
NO-1886 is used as an antiatherogenic agent for reducing the risk of atherosclerosis, a condition characterized by the buildup of plaque in the arteries, leading to heart disease and stroke.
NO-1886 is used as an antiobesity agent for promoting weight loss and managing obesity-related health issues.
NO-1886 is used as an antidyslipidemia agent for regulating lipid levels in the blood, reducing the risk of cardiovascular diseases.
NO-1886 is used as an anticachexia agent for managing cachexia, a condition characterized by muscle wasting and weight loss, often associated with chronic diseases.
NO-1886 is used as an antidiabetes/syndrome agent for managing diabetes and related metabolic disorders.
Used in Cosmetic Industry:
NO-1886 is used as a lipoprotein lipase activator for promoting the breakdown of fats and enhancing the absorption of essential nutrients in the skin.
Used in Food Industry:
NO-1886 can be used as a functional ingredient in food products to promote health benefits, such as weight management, improved lipid profile, and reduced risk of cardiovascular diseases.

InChI:InChI=1/C19H20BrN2O4P/c1-3-25-27(24,26-4-2)13-14-5-7-15(8-6-14)19(23)22-18-10-9-17(20)11-16(18)12-21/h5-11H,3-4,13H2,1-2H3,(H,22,23)

Upstream product

• 39263-32-6 2-amino-5-bromobenzonitrile 
• 118578-91-9 4-[(diethoxyphosphoryl)-methyl]benzoyl chloride 
• 28149-48-6 4-[(diethoxyphosphinyl)methyl]benzoic acid 
• 1122-58-3 dmap 

Downstream Products

• 166394-32-7 [4-(6-Bromo-4-hydroxy-quinazolin-2-yl)-benzyl]-phosphonic acid diethyl ester 

Relevant academic research and scientific papers

Agent for preventing and curing fatty liver and method for curing thereof

The present invention provides an agent for preventing and curing fatty liver containing, as the effective ingredient compound, a carboxylic acid amide derivative represented by the general formula (1), (wherein R is a lower alkyl group; and X is a halogen atom), and a method for curing fatty liver by administering said agent.

Composition for preventing and treating cataract

The present invention provides an agent for preventing and treating cataract comprising, as an active ingredient, a carboxylic acid amide derivative represented by the general formula: STR1 wherein R1, R2, R3, R4/sup

Phosphonic diester derivatives

The present invention provides a phosphonic diester derivative of the following general formula (1): STR1 wherein A represents an oxygen atom or a sulfur atom; R1, R2, R9 and R10 are the same or different and th

Synthesis and hypolipidemic activities of novel 2-[4-[(diethoxyphosphoryl)methyl]phenyl]quinazolines and 4(3H)-quinazolinones

The novel compound NO-1886, 4-[(diethoxyphosphoryl)methyl]-N-(4-bromo-2-cyanophenyl)-benzamide, is a hypolipidemic agent, which appears to increase lipoprotein lipase activity in rats. Various analogs of NO-1886 were synthesized to study the structure-act

Method for treating hyperlipidemia

A pharmaceutical composition for treating hyperlipidemia containing, as the active ingredient, at least one carboxamide compounds represented by the formula (1) which possess excellent activities in lowering serum lipid, as well as having low toxicity with high safety. Said carboxamide compounds represented by the formula (1) are known compounds developed by the present inventors, but the pharmacological activities for treating hyperlipidemia have not been found yet.

Carboxamide derivatives

Carboxamide derivatives, suitable for use in the treatment of hyperliidemia have the formula: (wherein R is a lower alkyl group; and X is a halogen atom).